Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ibrutinib Tablet vs Capsule
NCT02877225Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenstrom macroglobulinemia (WM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Area Under Concentration from time zero to the last quantifiable concentration, Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time and 4 more. Started Aug 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02877225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877225.